FDA Approval Sought for Daratumumab/Rd for Frontline Transplant-Ineligible Myeloma - OncLive

FDA Approval Sought for Daratumumab/Rd for Frontline Transplant-Ineligible Myeloma  OncLive

A supplemental Biologics License Application (sBLA) has been initiated with the FDA for daratumumab (Darzalex) for use in combination with lenalidomide ...



Comments

Popular posts from this blog

Epidemiology and prevention of venous thromboembolism